Canaccord Genuity Reiterates a 'Hold' on Protalix BioTherapeutics (PLX); Modest U.S. But Strong In Israel

Article Stock Quotes (2) Comments (0)

Canaccord Genuity reiterates a 'Hold' on Protalix BioTherapeutics (NYSE: PLX) price target of $6.00 (from $8.00).

Analyst, Ritu Baral, said, "We see modest US but robust Israel & ROW sales potential; EU delayed to 2016. We think PLX/partner Pfizer's (NYSE: PFE) Elelyso (taliglucerase) may ultimately get ~15% of the $1.2B+ worldwide Gaucher's market. We are lowering our target to $6 due to later-than-expected ROW sales. Our target is based on a DCF of projected US/ROW sales and pNPV of future EU sales."

For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.

Shares of Protalix BioTherapeutics closed at $6.19 yesterday, with a 52 week range of $4.06-$7.70.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
• Compass Point Boosts Numbers on RLJ Lodging Trust (RLJ)
• SunPower (SPWR) Not Worth More than $13/Share, Says Goldman

Create E-mail Alert Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Canaccord Genuity

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?